Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.

@article{Todd1997GlucagonlikeP,
  title={Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.},
  author={J Freeborn Todd and John P H Wilding and Christina M. Edwards and Fuad A. Khan and M. A. Ghatei and Stephen R Bloom},
  journal={European journal of clinical investigation},
  year={1997},
  volume={27 6},
  pages={
          533-6
        }
}
  • J Freeborn Todd, John P H Wilding, +3 authors Stephen R Bloom
  • Published in
    European journal of clinical…
    1997
  • Medicine
  • Glucagon-like peptide-1 (7-36) amide (GLP-1) is released from the gut into the circulation after meals and is the most potent physiological insulinotropic hormone in man. In contrast to presently available therapeutic agents for non-insulin-dependent diabetes mellitus (NIDDM), GLP-1 has the advantages of both suppressing glucagon secretion and delaying gastric emptying. We report the first chronic study of subcutaneous (s/c) GLP-1 treatment in NIDDM. Five patients with poorly controlled NIDDM… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 51 CITATIONS, ESTIMATED 40% COVERAGE

    The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Gut hormones as therapeutic agents in treatment of diabetes and obesity.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    1998
    2017

    CITATION STATISTICS

    • 1 Highly Influenced Citations